Study tests targeted treatments for NF2 tumors
Treatments studied
Part of Brain & nervous system, Cancer, Ear, nose & throat, Genetic & congenital clinical trials.
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have NF2 confirmed by a genetic NF2 test or by specific NF2 diagnosis rules (NIH or Manchester criteria)
- You have a “target” NF2-related tumor that has been growing on MRI in the last 36 months
- Your tumor is measurable on MRI (size must meet the study’s minimum measurement rules)
- Your tumor is not a good candidate for surgery right now (either you choose not to have surgery or surgery is too risky)
- You can take part in the study and sign consent (and assent if age 12–17), and have enough overall health (Karnofsky ≥70 or ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at new medicines for people with NF2-related schwannomatosis (NF2-SWN), a condition that causes tumors on nerves. It aims to track how tumors grow over time and test potential treatments.
This trial tests a drug called selumetinib for people with a rare genetic condition called NF2-related schwannomatosis, which causes non-cancerous tumors on nerves. The study focuses on shrinking or slowing the growth of these tumors, especially those affecting hearing, and is for patients who cannot have surgery or choose not to.
This trial tests a combination of two drugs (Luvometinib and Serplulimab) for people with NF2 (Neurofibromatosis type 2) who have growing brain tumors (vestibular schwannoma or meningioma) that cannot be safely removed with surgery. The goal is to see if this drug combination can shrink or slow the growth of these tumors.
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
This trial tests an oral drug called FCN-159 for people with NF2-related nerve sheath tumors that cannot be fully removed by surgery or have come back after surgery. It aims to see if the drug can shrink or slow the growth of these tumors.
This trial tests a new drug called PRG-N-01 for people with Neurofibromatosis Type 2 (NF2) who have growing or symptomatic tumors but cannot have surgery. The goal is to find the best dose and see if the drug can help shrink or control the tumors.
Hear when a new Vestibular Schwannoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.